Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
17.58
-0.96 (-5.18%)
At close: Nov 20, 2026, 4:00 PM EST
18.00
+0.42 (2.39%)
After-hours: Nov 20, 2026, 7:30 PM EST
Caris Life Sciences Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Caris Life Sciences stock has a consensus rating of "Buy" and an average price target of $34.23. The average 1-year stock price forecast is 94.71% higher than the current stock price, while the lowest is $25 (+42.21%) and the highest is $38 (+116.15%).
Price Target: $34.23 (+94.71%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Caris Life Sciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Reiterates $22 → $25 | Hold | Reiterates | $22 → $25 | +42.21% | Nov 10, 2026 |
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Reiterates $36 | Buy | Reiterates | $36 | +104.78% | Nov 10, 2026 |
Albert Hu Citi | Citi | Buy Maintains $28 → $36 | Buy | Maintains | $28 → $36 | +104.78% | Nov 6, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Nov 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $30 | Hold | Maintains | $30 | +70.65% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
1.05B
from 812.03M
Increased by 28.81%
Revenue Next Year
1.25B
from 1.05B
Increased by 19.11%
EPS This Year
0.12
from -0.41
EPS Next Year
0.30
from 0.12
Increased by 163.36%
EPS and Forward PE are based on non-GAAP adjusted numbers.